Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of December 31, 2021, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details:
- Issued Share Capital: 5,387,015,059 Ordinary Shares of 25 pence each as of December 31, 2021.
- Treasury Shares: 355,205,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,031,809,109.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,031,809,109) to determine if disclosure thresholds for shareholding interests have been met.
- Confirm the number of shares held in Treasury (355,205,950) when calculating the free float or outstanding share count.
- Note that this filing does not contain operational or financial performance results for the period.